Thinly traded nano cap Enlivex Therapeutics (ENLV -5.6%) announces that
it, along with the Head of Israel Economic and Commercial Mission to
South Korea, has submitted a proposal to South Korean authorities
regarding the potential use of Allocetra in COVID-19 patients
hospitalized in ICUs and suffering from organ dysfunction/failure.
The company is developing Allocetra,
an immunotherapy designed to avert cytokine storms (excessive and
life-threatening immune responses) and restore immune balance, for the
potential treatment of patients with organ failure due to sepsis.
Investors’ reaction to yesterday’s announced equity offering appears to be carrying over today.
https://seekingalpha.com/news/3548102-enlivex-proposes-use-of-allocetra-for-critically-ill-covidminus-19-patients
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.